TP53 and neoplasm: Downregulation of RanBP2 was shown to be related to perturbing tumor progression in mice, which indicates that disruption in the SUMO pathway prevents malignancy [72].This has been deemed to be a consequence of the potential for direct and indirect regulation by SUMOylation of p53.